Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma
Madeira MH, Ortin-Martinez A, Nadal-Nícolas F, Ambrósio AF, Vidal-Sanz M, Agudo-Barriuso M, Santiago AR
Scientific reports · 58 citations
How it was studied
- Design
- Animal study (classified by our AI screen)
- Studied in
- Animals
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- Ministerio de Economía y Competitividad
- Government
- Fundação para a Ciência e a Tecnologia
- Government
- Instituto de Salud Carlos III
- Grants
- Fundação para a Ciência e a Tecnologia (04539); Fundação para a Ciência e a Tecnologia (COMPETE); Fundação para a Ciência e a Tecnologia (PTDC/BIM-MEC/0913/2012); Instituto de Salud Carlos III (RD 12/0034); Instituto de Salud Carlos III (PI13/00643); Fundação para a Ciência e a Tecnologia (UID/NEU/04539/2013); Instituto de Salud Carlos III (RD12/0034/0014); Ministerio de Economía y Competitividad (RD12/0034); Ministerio de Economía y Competitividad (PI13/00643); Fundação para a Ciência e a Tecnologia (FCOMP-01-0124-FEDER); Ministerio de Economía y Competitividad (RD12/0034/0014)
Based on 3 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2016-06-08 · Sci Rep · vol. 6 · issue 1 · p. 27532
- Publisher
- Nature Portfolio
- Cited
- 69 citations · more than 97% of similar papers · 6.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 68 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Retinal Diseases and Treatments · Glaucoma and retinal disorders · Ocular Surface and Contact Lens
- Keywords
- Glaucoma, Medicine, Caffeine, Neuroinflammation, Retinal ganglion cell, Retinal, Neuroprotection, Ocular hypertension, Intraocular pressure, Pharmacology, Intravitreal administration, Optic nerve, Adenosine receptor antagonist, Retina, Ophthalmology, Neuroscience, Adenosine receptor, Receptor, Endocrinology, Internal medicine, Biology, Inflammation
- MeSH
- central nervous system, retinal ganglion cells, retina, animals, humans, rats, rats, sprague-dawley, glaucoma, disease models, animal, inflammation, nerve degeneration, caffeine, intraocular pressure
7 authors
From PT, ES
- Maria Helena MadeiraUniversity of Coimbra
- Arturo Ortín-MartínezInstituto Murciano de Investigación Biosanitaria; Universidad de Murcia
- Francisco Manuel Nadal-NicolásInstituto Murciano de Investigación Biosanitaria; Universidad de Murcia
- António Francisco AmbrósioAssociation for Innovation and Biomedical Research on Light and Image; University of Coimbra
- Manuel Vidal‐SanzInstituto Murciano de Investigación Biosanitaria; Universidad de Murcia
- Marta Agudo‐BarriusoInstituto Murciano de Investigación Biosanitaria; Universidad de Murcia
Abstract
Glaucoma is the second leading cause of blindness worldwide, being characterized by progressive optic nerve damage and loss of retinal ganglion cells (RGCs), accompanied by increased inflammatory response involving retinal microglial cells. The etiology of glaucoma is still unknown, and despite elevated intraocular pressure (IOP) being a major risk factor, the exact mechanisms responsible for RGC degeneration remain unknown. Caffeine, which is an antagonist of adenosine receptors, is the most widely consumed psychoactive drug in the world. Several evidences suggest that caffeine can attenuate the neuroinflammatory responses and afford protection upon central nervous system (CNS) injury. We took advantage of a well characterized animal model of glaucoma to investigate whether caffeine administration controls neuroinflammation and elicits neuroprotection. Caffeine or water were administered ad libitum and ocular hypertension (OHT) was induced by laser photocoagulation of the limbal veins in Sprague Dawley rats. Herein, we show that caffeine is able to partially decrease the IOP in ocular hypertensive animals. More importantly, we found that drinking caffeine prevented retinal microglia-mediated neuroinflammatory response and attenuated the loss of RGCs in animals with ocular hypertension (OHT). This study opens the possibility that caffeine or adenosine receptor antagonists might be a therapeutic option to manage RGC loss in glaucoma.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.